anti-tumor effectiveness
ASCO 2023: Patients with HER2-Positive MCRC Benefit from Lower Dose of Trastuzumab Deruxtecan
SG Tylor
ABSTRACT NUMBER – 3501 The Phase II DESTINY-CRC02 study, presented at the 2023 ASCO Annual Meeting, reported that administering ENHERTU ...
